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Insulin Regulates Adrenal 
Steroidogenesis by Stabilizing SF-1 
Activity
Ann W. Kinyua1, Khanh V. Doan1,4, Dong Joo Yang1,2, My Khanh Q. Huynh1, Yun-Hee Choi3, 
Dong Min Shin2 & Ki Woo Kim  1,2
Development of metabolic syndrome is associated with hyperactivity of the HPA axis characterized 
by elevated levels of circulating adrenal hormones including cortisol and aldosterone. However, the 
molecular mechanism leading to the dysregulation of the HPA axis is not well elucidated. In this study, 
we found that insulin regulates adrenal steroidogenesis by increasing the expression and activity of 
steroidogenic factor 1 (SF-1) both in vitro and in vivo and this insulin effect was partly through inhibition 
of FoxO1. Specifically, insulin increased the protein and RNA levels of SF-1 and steroidogenic target 
genes. Further, adrenal SF-1 expression was significantly increased by hyperactivation of insulin 
signaling in mice. Together with the elevated SF-1 expression in adrenal glands, hyperactivation of 
insulin signaling led to increased aldosterone and corticosterone levels. On the other hand, suppressing 
the insulin signaling using streptozotocin markedly reduced the expression of adrenal SF-1 in mice. 
In addition, overexpression of FoxO1 significantly suppressed SF-1 and its steroidogenic target genes 
implying that the positive effect of insulin on SF-1 activity might be through suppression of FoxO1 in 
the adrenal gland. Taken together, these results indicate that insulin regulates adrenal steroidogenesis 
through coordinated control of SF-1 and FoxO1.
The activity of the hypothalamic-pituitary-adrenal (HPA) axis is dysregulated in obese and diabetic patients as well 
as in different animal models predisposed to metabolic syndrome including ob/ob mice and Zucker fatty rat1–3. 
Emerging evidence in the last few decades has shown a close relationship between disorders of the HPA axis and 
the development of metabolic syndrome as demonstrated by similarities in clinical features of Cushing syndrome 
and obesity. Cushing syndrome results from the overproduction of adrenocorticotropic hormone (ACTH) by 
the pituitary glands with the concomitant hypersecretion of cortisol by adrenal glands and is associated with 
glucose intolerance, hyperlipidemia and hypertension4. On the other hand, obesity is associated with an increase 
in the secreted levels of the adrenal gland hormones including cortisol5–7 which is known to increase abdominal 
fat mass by stimulating the differentiation of preadipocytes to mature adipocytes8. The adrenal gland is therefore 
considered a key player in the development of metabolic syndrome owing to the role of the adrenal hormones in 
energy and metabolic homeostasis.
Steroidogenic factor 1 (SF-1) is a transcriptional factor belonging to the nuclear receptor superfamily and is 
predominantly expressed in the adrenal glands, gonads, pituitary gland and ventromedial hypothalamus (VMH). 
SF-1 plays an important role in steroid hormones synthesis by regulating the transcription of steroidogenic genes 
including StAR, Cyp11a1, Cyp17, Cyp11b1, Cyp11b2 and 3β-Hsd9,10. In addition, SF-1 functions as a metabolic 
regulator in the brain particularly in the VMH where SF-1 expressing neurons are widespread11,12.
The pancreatic hormone insulin is well known for its role in energy metabolism regulation among other phys-
iological functions13,14. Previous studies have suggested the involvement of insulin in gonadal steroidogenesis15,16. 
However, the molecular mechanism mediating the insulin effect on steroidogenesis as well as the physiological 
implication remains to be elucidated. In addition, the role of insulin in regulating the production of adrenal hor-
mones, and the underlying molecular mechanism, has not been clearly demonstrated. In this study we therefore 
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sought to address the role of insulin in steroidogenesis by focusing on adrenal steroidogenesis and metabolic 
regulation. Our data indicates that insulin regulates adrenal steroidogenesis by up regulating the transcriptional 
activity of SF-1 both in vitro and in vivo. Further, we show that overexpression of FoxO1, a downstream transcrip-
tion factor regulated by insulin, inhibits the expression and transcriptional activity of SF-1 suggesting that insulin 
might increase the activity of SF-1 by phosphorylating and inactivating FoxO1. Therefore, our findings propose 
the insulin-FoxO1 pathway as a possible mechanism regulating adrenal hormones production and metabolic 
homeostasis that is distinct from the canonical cAMP/PKA pathway.
Results
Insulin upregulates SF-1 and steroidogenic target genes. To investigate the role of insulin in adre-
nal steroidogenesis, we treated Y1 cells with insulin for 24 h and examined the expression of genes involved in 
steroidogenesis. Interestingly, insulin markedly up-regulated SF-1 as well as the SF-1 target genes including StAR, 
Cyp11a1, Cyp11b1, Cyp11b2, and Hsd3b2 all of which are important for adrenal steroidogenic pathway (Fig. 1a). 
As SF-1 is a known master regulator of steroidogenesis17, we monitored the SF-1 protein expression after treating 
Y1 cells with insulin for 24 h in a dose-dependent manner and also treating 100 nM insulin time dependently. 
Intriguingly, insulin markedly increased SF-1 protein level dose dependently (Fig. 1b and c). In addition, insulin 
significantly increased SF-1 time dependently with the strongest effect observed from 24–48 h (Fig. 1d and e). 
The effect of insulin was accompanied by the phosphorylation of AKT and FoxO1, direct downstream effectors 
of insulin signaling (Fig. 1b and d). We then tested the effect of insulin on DAX-1 which is a known SF-1 inhibi-
tor16,18. We however did not observe any changes on DAX-1 protein by insulin treatment suggesting that the effect 
of DAX-1 on insulin-mediated SF-1 regulation might be minimal. In addition, treatment of 8Br-cAMP led to an 
increase in SF-1 protein level accompanied by phosphorylation of CREB while 24 h insulin treatment stimulated 
the expression of SF-1 in a manner independent of the canonical steroidogenic cAMP/PKA/pCREB pathway19 
(Fig. 1f). These results highly suggest that insulin might positively regulate the expression of steroidogenic genes 
by enhancing PKA-independent SF-1 function.
Insulin stimulates steroidogenic genes expression in SF-1 dependent manner. The insulin 
mediated increase in SF-1 protein and mRNA levels led us to investigate the effect of insulin on the transcrip-
tional activity of SF-1 by performing luciferase assays. Insulin markedly increased SF-1 luciferase activity in a 
Figure 1. SF-1 and steroidogenic genes are increased by insulin. Relative gene expression of SF-1 and 
steroidogenic SF-1 target genes after 24 h insulin treatment (a). Dose (b and c) and time (d and e) dependent 
effects of insulin on SF-1 and DAX1 protein levels. Note that the activation of insulin signaling was confirmed 
by phosphorylation of AKT and FoxO1. Effect of insulin and 8Br-cAMP (100 uM) on SF-1 protein levels (f). 
100 nM of insulin was used for experiments unless otherwise specified. All experiments were performed in 
triplicates. Original Western blots are provided in the Supplementary information. The values are mean ± SEM 
(*p < 0.05, Student’s t-test).
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dose-dependent manner (Fig. 2a). Cyp11b1, an enzyme involved in the synthesis of corticosterone was also sig-
nificantly increased in the presence of SF-1 and insulin (Fig. 2b and Supplementary Fig. S1a). Consistent with 
the exogenous SF-1 overexpression, Cyp11b1 activation was up-regulated by insulin treatment in Y1 cells in 
which SF-1 is expressed endogenously (Fig. 2c). To investigate whether the increased expression of steroido-
genic genes by insulin was dependent on SF-1, we knocked down SF-1 and then treated insulin (Fig. 2d and e). 
Up-regulation of steroidogenic genes including StAR, Cyp11a1, Cyp11b1, Cyp11b2, and Hsd3b2 by insulin was 
markedly blunted by SF-1 knockdown indicating that SF-1 is required for the effect of insulin on adrenal steroi-
dogenic genes (Fig. 2e).
Insulin-mediated FoxO1 suppression is critical for steroidogenic genes expression. To gain fur-
ther molecular insight into how insulin positively regulates steroidogenesis, we pre-treated cells with 1 uM of 
MK2206, an AKT inhibitor, for 1 h and measured the luciferase activity of Cyp11b1 with or without insulin treat-
ment. The insulin-mediated increase in Cyp11b1 activity was significantly blunted by the AKT inhibitor, imply-
ing that the insulin/AKT pathway might be important for regulation of steroidogenic genes activities (Fig. 3a). 
FoxO1 is phosphorylated by AKT upon activation of insulin signaling and its transcriptional activity is inhibited 
through cytoplasmic localization by insulin. In addition, previous studies have shown that FoxO1 negatively reg-
ulates SF-1 activity in the ventromedial hypothalamus (VMH)20. Therefore, we postulated that the upregulation 
of SF-1 and its steroidogenic target genes by insulin might be as a result of phosphorylation and inactivation of 
FoxO1 by insulin. To investigate the effect of FoxO1 on SF-1 and steroidogenic target genes, we introduced the 
constitutively active form of FoxO1 (FoxO1-CA), in which the phosphorylation sites are mutated and is therefore 
always localized in the nucleus21 and examined the luciferase activity of SF-1. FoxO1-CA markedly blunted the 
transcriptional activity of SF-1 from a low dose of 50 ng (Fig. 3b) and exhibited continuous suppressive effect up 
to 1 ug. We next overexpressed FoxO1-WT or FoxO1-CA with or without insulin and examined transcriptional 
activity of Cyp11b1. FoxO1-WT significantly inhibited the promoter activity of Cyp11b1 and further repressive 
effect was shown by FoxO1-CA (Fig. 3c and d). Additionally, the repressive effect of FoxO1-WT and FoxO1-CA 
resulted in significant suppression of SF-1 mRNA levels as well as steroidogenic target genes including StAR, 
Cyp11a1, Cyp11b1, Cyp11b2, and Hsd3b2 (Fig. 3e–g). Taken together, these data highly suggests that FoxO1 
negatively regulates the expression of SF-1 and steroidogenic genes and that suppression of FoxO1 by insulin 
treatment might stimulate steroidogenesis, at least in part, through activation of SF-1.
Figure 2. Insulin increases the transcriptional activity of SF-1. Dose-dependent effect of insulin on SF-1 
transcription in HEK293 cells (a). Increase in Cyp11b1 transcriptional activity by time-dependent insulin 
treatment after co-transfection of SF-1 (b). Relative luciferase activity of Cyp11b1 after insulin treatment in 
Y1 cells (c). Effect of insulin on SF-1 and steroidogenic genes after knocking down SF-1 (d and e). The values 
are mean ± SEM (*p < 0.05, Student’s t-test, one-way ANOVA). EV, empty vector. SF-1-Luc, SF-1 luciferase 
construct. Cyp11b1-Lu, Cyp11b1 luciferase construct.
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Stimulation of adrenal steroidogenesis by activation of insulin signaling. To confirm our findings 
that insulin stimulates steroidogenesis and to examine the effect of insulin on adrenal steroidogenesis in vivo, 
we generated a mouse model mimicking increased insulin activity by feeding mice on high fat diet (HFD) for 
8 weeks. HFD led to a pronounced increase in plasma insulin levels (Fig. 4a and d) and this was accompanied 
by a marked hyperactivation of insulin signaling pathway specifically in the adrenal gland, soleus muscle, and 
Figure 3. Suppressive effects of FoxO1 on steroidogenic genes expression. Pre-treatment of MK2206 
(1 uM) significantly blunted the Cyp11b1 transcriptional activity induced by insulin treatment in HEK 293 
cells (a). Dose-dependent effect of FoxO1-CA on the SF-1 promoter activity in HEK 293 cells (b). Effect of 
FoxO1-WT on Cyp11b1 promoter activity in Y1 cells (c). FoxO1-CA significantly suppressed the Cyp11b1 
promoter activity mediated by insulin in Y1 cells (d). Overexpression of FoxO1-WT suppressed the expression 
of steroidogenic genes including SF-1, StAR, Cyp11a1, Cyp11b1, Cyp11b2, and Hsd3b2 in Y1 cells (e). 
Overexpression of FoxO1-CA blunted the insulin-mediated increase of the steroidogenic genes such as SF-1, 
StAR, Cyp11a1, Cyp11b1, Cyp11b2, and Hsd3b2 in Y1 cells (f). Western blot for FoxO1-WT or FoxO1-CA 
confirming the overexpression experiments in Fig. 3e and f (g). The values are mean ± SEM (*p < 0.05 Student’s 
t-test, #p < 0.05 one-way ANOVA).
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liver as shown by the significant increase in phosphorylation of AKT and FoxO1 in both male and female mice 
(Fig. 4b,c,e and f and Supplementary Fig. S2). The hyperactivation of insulin pathway by short-term HFD expo-
sure clearly showed inactivation of FoxO1 and was accompanied by a significant increase of SF-1 in the adrenal 
gland (Fig. 4b,c,e and f). Corresponding with the elevated SF-1 protein levels in the adrenal gland, the mRNA 
levels of steroidogenic genes were also significantly elevated (Fig. 4g and Supplementary Fig. S3). Together with 
the increase in expression of steroidogenic genes, plasma aldosterone and corticosterone levels were highly ele-
vated in male and female mice (Fig. 4h and i and Supplementary Fig. S3). Next, we generated a mouse model 
mimicking blunted insulin signaling by injecting mice with streptozotocin (STZ) for 5 days. STZ injection led to 
a marked reduction in serum insulin levels (Fig. 4j). Importantly, SF-1 protein and mRNA levels in the adrenal 
gland were markedly reduced in the STZ-injected mice (Fig. 4k–o). The blunted insulin signaling in adrenal gland 
was confirmed by the decreased levels of pAKT and pFoxO1 (Fig. 4k–n). Therefore, our results highly suggest that 
insulin positively regulates the expression of SF-1, and the phosphorylation and inactivation of FoxO1 through 
the insulin signaling might be an underlying mechanism mediating the expression and activity of SF-1.
Figure 4. Regulation of adrenal steroidogenesis by insulin. Plasma insulin levels in male mice fed normal 
chow (NC) or HFD for 8 weeks (n = 4–6) (a). Protein levels of indicated proteins from the adrenal gland (b). 
Densitometry of the protein intensity from (b) in male mice (c). Plasma insulin levels in female mice fed NC or 
HFD for 8 weeks (n = 4–6) (d). Protein levels of indicated proteins from the adrenal gland (e). Densitometry 
of the protein intensity from (e) in female mice (f). mRNA expression of indicated steroidogenic genes from 
the adrenal gland (g). Plasma aldosterone (h) and corticosterone (i) levels from male mice fed on NC or HFD. 
Plasma insulin levels of mice injected with streptozotocin (+STZ, n = 7) and mice injected with sodium 
citrate as control for vehicle (−STZ, n = 5) (j). Protein levels of indicated proteins from the adrenal gland (k). 
Densitometry of the indicated proteins (l–n). Relative mRNA expression of SF-1 from the adrenal gland (o). All 
the corresponding original Western blot images are provided in the Supplementary information. The values are 
mean ± SEM (*p < 0.05, Student’s t-test).
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Discussion
The synthesis and secretion of adrenal steroid hormones is coordinated by three organs, the hypothalamus, ante-
rior pituitary and adrenal glands referred to as the HPA axis. The hypothalamus secretes corticotrophin releasing 
hormone (CRH) which stimulates the release of adrenocorticotropic hormone (ACTH) from the pituitary gland. 
ACTH in turn acts through the melanocortin 2 receptors (MC2R) expressed on the adrenal glands leading to an 
increase in cAMP and activation of protein kinase A followed by the transcription of steroidogenic genes and 
subsequent synthesis of steroid hormones22. Impaired adrenal steroidogenesis has detrimental effects on glucose 
and energy homeostasis4. On the other hand, dysregulation of metabolic homeostasis is associated with increased 
secretion of adrenal hormones showing a correlation between dysregulation of HPA axis and metabolic syndrome 
development5–7.
In addition to the canonical steroidogenic pathway, various factors have been shown to contribute to steroid 
hormones synthesis23–27. Although these studies focused on the factors involved in steroidogenesis, the direct 
molecular mechanisms linking metabolic hormones to adrenal steroidogenesis has not been conclusively shown. 
As metabolic diseases including diabetes and obesity are associated with dysregulation of adrenal steroids, we 
postulated that metabolic hormones including insulin might directly influence adrenal steroidogenesis. In the 
current study, we show that insulin directly regulates adrenal steroidogenesis by activating SF-1 and its steroido-
genic target genes through a mechanism that might be independent of the canonical CRH/ACTH/MC2R/PKA 
pathway. To address the role of insulin on adrenal steroidogenesis, we focused on SF-1 which plays an important 
role in steroid hormones production as it regulates the genes involved in the steroidogenesis17. Insulin treatment 
markedly increased SF-1 and steroidogenic target genes and this increase was dependent on SF-1 as knockdown 
of SF-1 failed to upregulate the expression of steroidogenic target genes by insulin (Figs 1 and 2). Together with 
the previous finding in which deletion of the insulin and insulin-like growth factor 1 receptor was associated with 
adrenal agenesis28, our findings suggests that insulin signaling is not only essential for the adrenal glands devel-
opment, but also required for adrenal steroidogenesis.
Previous studies have shown that FoxO1 negatively regulates the transcription of ovarian steroidogenic genes 
including luteinizing hormone β-subunit (LHβ) and the follicle stimulating hormone β (FSH β)29,30. In addition, 
FoxO1 was shown to suppress the expression of SF-1 in the ventromedial hypothalamus (VMH)20. This infor-
mation led to our hypothesis that insulin might regulate the function of FoxO1, a direct downstream effector of 
insulin signaling, and thereby affect steroidogenic genes in adrenal glands. Therefore, we focused on the role of 
transcriptional factor FoxO1 in regulation of SF-1 expression and adrenal steroidogenesis. To address the role of 
FoxO1 on adrenal steroidogenesis, we overexpressed the wild-type form of FoxO1 (FoxO1-WT) and the constitu-
tively active form of FoxO1 (FoxO1-CA) and measured the expression and activity of SF-1 and SF-1 target genes. 
Overexpression of FoxO1 significantly blunted the expression of SF-1 as well as steroidogenic SF-1 target genes. 
Similarly, FoxO1-WT and FoxO1-CA blunted the luciferase activity of SF-1 and Cyp11b1 (Fig. 3). Further, over-
expression of FoxO1-CA significantly suppressed the elevation of SF-1 and its steroidogenic targets induced by 
insulin treatment (Fig. 3). These data suggest that the suppressive effect of FoxO1 on SF-1 and steroidogenic genes 
is blunted by insulin treatment. However, whether the effect of FoxO1 on steroidogenic genes is solely mediated 
through disinhibition of SF-1 activity requires to be further explored.
To understand the insulin-induced increase in adrenal steroids production observed in vitro, we set up a 
mouse model mimicking hyper-activation of insulin signaling pathway by challenging mice with HFD for 8 
weeks. HFD exposure was accompanied by a significant increase in insulin levels and exhibited significant activa-
tion of insulin pathway illustrated by marked phosphorylation of AKT and FoxO1 in the adrenal gland. Having 
confirmed the activation of insulin signaling by HFD exposure, we then monitored the expression of SF-1 and 
steroidogenic target genes in the adrenal gland. As shown in Fig. 4, SF-1 and other genes involved in steroi-
dogenesis including StAR, Cyp11a1, Cyp11b1, Cyp11b2, and Hsd3b2 were significantly increased (Fig. 4 and 
Supplementary Fig. S3). In addition, the serum levels of adrenal steroid hormones such as aldosterone and corti-
costerone were significantly elevated in the HFD fed mice (Fig. 4 and Supplementary Fig. S3). Consistently, low 
insulin condition induced by STZ administration showed a marked reduction in SF-1 levels (Fig. 4j–o). Therefore, 
our results highly imply that activation of insulin signaling might be directly involved, at least in part, in the 
regulation of steroidogenesis in the adrenal gland. In addition, it is important to note that there is possibility that 
insulin could be indirectly involved in steroidogenesis through insulin-induced hypoglycemia since hypoglyce-
mia activates the HPA axis with the concomitant increase in corticosterone levels31,32. Therefore further studies to 
establish the effect of insulin on the HPA axis would provide further insight into the regulation of steroidogenesis 
regulated by insulin.
This study shows that FoxO1 negatively regulates adrenal steroidogenesis partly through suppression of SF-1. 
This finding warrants further studies to investigate the direct effects of FoxO1 on the transcription of steroido-
genic genes as well as the interaction between steroidogenic genes and other members of the FoxO family in 
the adrenal gland. Further, clinical analysis on the expression pattern of FoxO1 and SF-1 in patients with obe-
sity and type 2 diabetes could shed more light on the relationship between HPA axis dysregulation and obesity 
development.
In summary, our data suggest that insulin contributes to the dysregulation of the HPA axis observed in met-
abolic syndrome by directly increasing the production of adrenal gland hormones through upregulation of 
SF-1 and the steroidogenic genes important for steroid hormone synthesis. We suggest that the insulin medi-
ated increase in SF-1 and steroidogenic targets might be a result of phosphorylation and inactivation of FoxO1 
through a mechanism that is independent of the canonical steroidogenic cAMP/PKA pathway.
Materials and Methods
Materials. Dulbecco’s Modified Eagle Medium (DMEM) was purchased from Hyclone Laboratories Inc. 
(Logan, UT, USA). Fetal bovine serum (FBS) and penicillin-streptomycin were obtained from Gibco Life 
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Technologies (Carlsbad, CA, USA). Insulin (Cat# I2643) and 8Br-cAMP (Cat# B5386) were purchased from 
Sigma (St. Louis, MO, USA). MK2206 was obtained from Sellekchem (Houston, TX, USA).
Cell culture. Y1 cells33 were cultured in DMEM enriched with 15% horse serum, 5% FBS and 1% 
penicillin-streptomycin. HEK 293 cells34 were grown in DMEM supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin-streptomycin. Both cell lines were maintained at 37 °C under 5% CO2. All in vitro experiments 
were performed in triplicates.
Luciferase assay. Y1 and HEK 293 cells were split in six-well plates at a density of 5 × 105 cells/well in 6-well 
plates and 3 × 105 cells/well in 12-well plates. The following day, cells were transfected with specific DNAs using 
Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA). Renilla was co-transfected as an internal 
control. Cells were harvested using luciferase lysis buffer composed of 25 mM Tris Phosphate pH 7.8, 2 mM 
DTT, 2 mM EDTA, 10% Glycerol and 1% Triton X-100. The relative firefly luciferase and renilla activities were 
recorded by the BioTek’s Synergy TM 2 machine (BioTek Instruments Inc., Winooski, VT, USA) following injec-
tion of luciferase and renilla substrates respectively34. The fold change was calculated as the ratio of firefly lucif-
erase and renilla activity normalized to the ratios obtained from control cells transfected with empty vector or 
treated with vehicle in case of drug treatments. Luciferase substrate (pH8.0) was composed of 200 mM Tris-HCL, 
15 mM MgSO4, 0.1 mM EDTA, 25 mM DTT, 1 mM ATP, 0.2 mM Coenzyme A and 200 uM Luciferin. Renilla 
substrate (pH 5.0) was composed of 1.1 M NaCl, 2.2 mM Na2EDTA, 0.22 M KH2PO4 (pH 5.1), 0.44 mg/ml BSA, 
1.3 mM Sodium Azide, 1.43 uM Coelenterazine35. The SF-1 luciferase construct is described previously20 and 
the Cyp11b1 luciferase construct was prepared by cloning the promoter region of human Cyp11b1 (−1102 bp) 
upstream of a luciferase reporter gene in pGL3 basic. FoxO1 wildtype (FoxO1-WT), constitutively active form 
of FoxO1 (FoxO1-CA) and a control vector pCMV5 used in the overexpression experiments were previously 
described20,34. The SF-1 DNA construct used was generated by cloning full length mouse SF-1 into a pcDNA 3.1 
vector as described and validated previously33,36.
Western blot. For protein expression analysis, Y1 cells were treated with the specific compounds, insulin and 
8Br-cAMP, time and dose dependently. Cells were harvested through trypsinization and lysed using RIPA buffer 
composed of 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate and 10% SDS 
containing protease and phosphatase inhibitor cocktails (Roche, Cat. No. 05892791001 and 04906837001 respec-
tively, Indianapolis, IN, USA). Equal amounts of protein were loaded and separated on a 10% SDS-PAGE gel 
and the protein levels were detected using enhanced chemiluminescence (ECL) following the standard Western 
blot procedure. Images were captured by UVP Bio-Spectrum 600 imaging system (Ultra-Violet Products Ltd. 
Cambridge, UK) after incubation with the antibodies listed below: pAKT (Cat. No. 4060S, 1:10,000), AKT (Cat. 
No. 2967S, 1:10,000), pFOXO1 (Cat. No. 9461, 1:2,000), FOXO1 (Cat. No. 2880S, 1:2,000) and pCREB (Cat. 
No.9196S, 1:2,000) from Cell Signaling (Danvers, MA, USA). DAX-1 (Cat. No. SC-841, 1:5,000) and GAPDH 
(Cat. No. SC-25778, 1:10,000) from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Flag (Cat. No. F1365, 
1:2,000) from Sigma (St. Louis, MO, USA). SF-1 protein was detected using rabbit antiserum as described pre-
viously37. Briefly, full length muse SF-1 cDNA containing an N-terminal 6× -His tag was cloned into a pET-
28a(+) vector and transformed overnight using Rosetta (Novagen) competent cells. The cells were harvested and 
the supernatant decanted for purification. Purified SF-1 protein was obtained by passing the supernatant over a 
Ni-His bind column and washing with 60 mM imidazole. The purified full length SF-1 protein was injected into 
rabbits and serum collected. Validation of the SF-1 antibody was conducted by immunohistochemistry analysis 
of SF-1 expression in wildtype and SF-1 knockout mouse models38. All the corresponding original Western blot 
images are provided in the Supplementary information.
RNA isolation and quantitative real time PCR. For quantitative real time PCR (Q-PCR) anal-
ysis, total RNA was isolated from cell or tissue samples using the Ambion Trizol reagent obtained from Life 
Technologies (Carlsbad, CA, USA) following the manufacturer’s protocol. cDNA was synthesized from 1 ug of 
total RNA with the high-capacity cDNA reverse transcription kit purchased from Applied Biosystems (Foster 
City, CA, USA). Q-PCR was performed using SYBR Green PCR master from Applied Systems using the follow-
ing mouse primers: 18S; 5′-AACCCGTTGAACCCCATT-3′ and 5′-CCATCCAATCGGTAGTAGCG-3′, SF-1; 
5′-CCCTTATCCGGCTGAGAATT-3′ and 5′-CCAGGTCCTCGTCGTACGA-3′, StAR; 5′-GTGGCTGCCGAAG 
ACAATC-3′ and 5′-AGGTGGTTGGCGAACTCTATC-3′, Cyp11a1; 5′-TGAATGACCTGGTGCTTCGT-3′ and 5′-G 
GCAAAGCTAGCCACCTGTA-3′, Cyp11b1; 5′-GAT ACA GAT CCT GAG GGA GC-3′ and 5′-CCG GCA ACG TCA 
CAA ACA CA-3′, Cyp11b2; 5′-CAGGGCCAAGAAAACCTACA-3′ and 5′-ACGAGCATTTTGAAGCACCT-3′, 
Hsd3b2;5′- CCAGGGCATCTCTGTTGTCAT-3′ and 5′-GGTTCTGGGTACCTTTCAGATTGA-3′. 18S was 
used for normalization of gene expression.
SF-1 gene silencing. The Y1 mouse adrenocortical tumor cells are known to endogenously 
express SF-133,36,39. To knockdown SF-1, Y1 cells were transfected with mouse SF-1 siRNA for 48 h using 
Lipofectamine 2000. The mouse SF-1 siRNA sequence 5′-CAUUACACGUGCACCGAGATT-3, as described 
previously39, was obtained from Cosmo Genetech (Seoul, South Korea). A non-target siRNA sequence 
5′UUCUCCGAACGUGUCACGUTT3′ was used as negative control.
Animal care. All the animal experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the Yonsei University Wonju College of Medicine. All experiments using mice were performed in 
accordance with the guidelines and regulations of the IACUC, Yonsei University Wonju College of Medicine. 
Mice were maintained in a controlled environment with room temperature at 22–23 °C and a 12 hour dark/light 
cycle. C57BL/6 male and female mice were randomly divided into two experimental groups (n = 4–6). One group 
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was maintained on normal chow (Zeigler, Gardners, PA, USA, Cat. No. Rodent NIH-31 Modified Auto, 4.02 kcal 
g−1) while the other group was fed on high fat diet (Research Diets, New Brunswick, NJ, USA, Cat. No. D12492, 
60% fat, 5.24 kcal g−1) for 8 weeks. An experimental group (n = 7) mimicking blunted insulin signaling was gen-
erated by injecting mice with either 50 mg/kg streptozotocin (STZ) (Sigma, St. Louis, MO, USA) for 5 days or 
with sodium citrate (control for vehicle, n = 5). Mice were sacrificed after decapitation and tissues collected for 
further analysis.
Hormone measurement. For corticosterone and aldosterone measurements, mice were housed in indi-
vidual cages overnight and blood samples were collected the following day at 2 pm. Corticosterone and aldos-
terone and levels were measured using ELISA kit obtained from Abcam (ab136933 and ab108821 respectively 
Cambridge, UK) according to the manufacturer’s instructions. Blood samples for insulin measurement were col-
lected at 10 am following decapitation and insulin levels were measured using ELISA kit obtained from Morinaga 
Institute of Biological Science (Yokohama, Japan) following the manufacturer’s protocol.
Statistical analysis. All results are expressed as mean ± SEM following analysis using the GraphPad Prism 
5.0 software. Statistical comparisons were made by the Student’s t-test or ANOVA and results with a p-value < 0.05 
were considered to be statistically significant.
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